With ongoing partnering discussion for the phase III trial with mitazalimab, Alligator Bioscience can put more focus on accelerating the development of ATOR-4066. To reach this goal, and push other pipeline projects further, the company now seeks to raise approximately SEK 150.9 million in a rights issue.

Read the article at biostock.se:

Alligator to maximise immuno-oncology innovation - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

https://news.cision.com/alligator-bioscience/r/biostock--alligator-to-maximise-immuno-oncology-innovation,c3952256

(c) 2024 Cision. All rights reserved., source Press Releases - English